orbactiv
Generic: oritavancin
orbactiv: developed by 1 company · 1 clinical trial tracked.
orbactiv evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect orbactiv to MLNT; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could orbactiv → MLNT affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
acute bacterial skin or skin structure infections (ABSSSI)
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) acute bacterial skin or skin structure infections (ABSSSI) | Approved |
Clinical Trials (1)
A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous Oritavancin for the Treatment of Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections
Primary endpoint: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
InterventionalRandomizedopen118 enrolledStarted 2023-06Completion 2025-1123 sites · Bulgaria, Greece, Latvia, Lithuania…Melinta Therapeutics, LLC
Frequently asked questions
Who is developing orbactiv?
orbactiv is being developed by MELINTA THERAPEUTICS, INC. /NEW/.
How many clinical trials involve orbactiv?
BioSniper tracks 1 clinical trial involving orbactiv.